![]() ![]() Corticosteroids play an essential role in the treatment of COPD, because of their excellent anti-inflammatory properties. įluticasone furoate is a potent glucocorticoid that is synthetic and chemically termed as triflourinated corticosteroid. ![]() Represent the mechanism of Inhaled corticosteroids. This review summarises the evidence on the safety, efficacy and other important pharmacological properties of this unique triple combination FDC product for use in severe COPD. It has the distinction of being the first fixed-dose triple combination approved by US FDA. A fixed dose combination of fluticasone furoate, umeclidinium and vilanterol (Trelegy Ellipta/GlaxoSmithKline) is a newly developed triple combination medication approved for use by US FDA for severe COPD patients in September 2017. According to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, the management of COPD depends on the severity of the disease and the rate of exacerbations leading to hospitalisation. The pharmacological treatment of COPD largely revolves around three categories of drugs namely inhaled corticosteroids, muscarinic antagonists, and β2-agonists. Few studies have shown that “the intensity of systemic inflammation in severe COPD patients, including large numbers of neutrophils, macrophages, and lymphocytes is directly affects the health-related quality of life, airflow limitation, exercise intolerance, and comorbidities associated with COPD”. ![]() ![]() At present it is not curable, it can only ease symptoms, improve health-related quality of life, and reduce the risk of mortality. There has been a somber forecast that, by 2060 over 5.4 million deaths would annually occur due to COPD and related conditions. In accordance with large epidemiological studies such as Burden of Obstructive Lung Disease (BOLD) showed that, with an increase in the prevalence of smoking in developing countries, the prevalence of COPD is expected to rise over the next 40 years. A 90% of COPD related deaths have occurred in low-income countries. Patients with COPD complain of persistent cough, sputum production, and dyspnea. The primary aetiology of COPD is smoking, though in recent times, many other additional factors have also been identified. The availability of a single inhaler device for delivering a triple combination of LABA/LAMA/ICS is a small success story in the quest to identify better therapies for patients with severe COPD, who are so prone to repeat acute exacerbations which could eventually turn fatal.Ĭhronic Obstructive Pulmonary Disease (COPD) is characterised by airway obstruction leading to persistent respiratory symptoms, on account of exposure to noxious substances. Nevertheless, it remains to be seen if this improved adherence would translate into improved outcomes such as reduced mortality in real world practice among patients with severe COPD. The convenience associated with using a single device for three different classes of drugs could be its biggest trump card and it will not be surprising to see its preference among patients avoiding the need for multiple dosing. Although this triple combination is used only in patients with the most advanced forms of disease who have frequent exacerbations and remain uncontrolled, there are certain additional indications that may be explored in future trials. This medication should be prescribed cautiously for certain populations. George questionnaire, and reduced hospitalisation due to acute exacerbation of COPD. Triple combination did show improvement through the mean Forced Expiratory Volume per divond (FEV1), St. Clinical trials comparing this triple combination with dual therapy including a Long Acting β2-Agonist/Long Acting Muscarinic Antagonist (LABA/LAMA) or Long Acting β2-Agonist/Inhaled Corticosteroids (LABA/ICS) were evaluated. Trelegy Ellipta (GlaxoSmithKlineTM) is the first single inhaler triple combination therapy comprising of umeclidinium, vilanterol and fluticasone approved by the United States Food and Drug Administration (US FDA) for patients with severe COPD in 2019. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |